Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse
Latest Information Update: 27 May 2025
At a glance
- Drugs Elacestrant (Primary) ; Anastrozole; Exemestane; Letrozole; Tamoxifen
- Indications Advanced breast cancer; Early breast cancer; HER2 negative breast cancer; Male breast cancer
- Focus Therapeutic Use
- Acronyms TREAT ctDNA
Most Recent Events
- 22 May 2025 According to a Menarini media release, data from this study will be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.
- 23 Jan 2024 Status changed from not yet recruiting to recruiting.
- 06 Nov 2023 Planned initiation date changed from 1 May 2023 to 15 Dec 2023.